SECsense Logo

NLS Pharmaceutics Ltd. Form 6-K Report: Key Takeaways from January 7, 2025 Meeting

$NLSP
Form 6-K
Filed on: 2025-01-07
Source
NLS Pharmaceutics Ltd. Form 6-K Report: Key Takeaways from January 7, 2025 Meeting

Here are the key insights extracted from the provided section of the financial report for NLS Pharmaceutics Ltd:

  1. Type of Filing: The document is a Form 6-K, which is a report of foreign private issuer filed with the SEC.
  2. Date of Report: The report is dated January 7, 2025.
  3. Company Information:
  • Name: NLS Pharmaceutics Ltd.
  • Address: The Circle 6, 8058 Zurich, Switzerland.
  1. Commission File Number: 001-39957.
  2. Extraordinary Shareholders' Meeting:
  • The extraordinary meeting took place on January 7, 2025.
  • A quorum was present at the meeting.
  • All agenda items were approved by shareholders, except for Proposal 6.
  • Proposal 6 was not voted on at the meeting.
  1. Incorporation by Reference: The report on Form 6-K is incorporated by reference into the company’s Registration Statements on Form F-3, under specific file numbers provided.
  2. Signature: The report is signed by Alexander Zwyer, the CEO of the company, affirming its authenticity.

These points highlight the critical information regarding the shareholders' meeting outcomes and the filing details relevant for investors and stakeholders involved with NLS Pharmaceutics Ltd.